Renovaro Inc. (NASDAQ:RENB – Get Free Report) shares were up 0.7% during trading on Friday . The company traded as high as $1.58 and last traded at $1.50. Approximately 307,430 shares changed hands during trading, an increase of 2% from the average daily volume of 300,902 shares. The stock had previously closed at $1.49.
Renovaro Price Performance
The stock has a market capitalization of $215.50 million, a price-to-earnings ratio of -2.14 and a beta of 0.44. The company has a 50-day simple moving average of $2.52 and a two-hundred day simple moving average of $3.11.
Renovaro (NASDAQ:RENB – Get Free Report) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.07) earnings per share for the quarter.
Renovaro Company Profile
Renovaro Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV.
Read More
- Five stocks we like better than Renovaro
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Manufacturing Stocks Investing
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- The How and Why of Investing in Biotech Stocks
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Renovaro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renovaro and related companies with MarketBeat.com's FREE daily email newsletter.
